Topical Cannabinoids for Epidermolysis Bullosa Keratin Upregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epidermolysis bullosa simplex (EBS) are limited in effectiveness, as they primarily focus on palliative care and do not address the underlying mechanical fragility caused by keratin protein dysfunction, leading to chronic blistering and increased risk of skin cancer.
Innovation Solution
Topical application of cannabinoids, specifically a mixture of cannabidiols and cannabinol, which modulates keratin gene expression and protein synthesis to compensate for dysfunctional keratins, thereby enhancing skin strength and reducing blister formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If topical cannabinoids are applied to treat EBS, then skin strength and wound healing are improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters of topical treatments - specifically using cannabinoids with specific ratios (e.g., CBD:CBN 10:1) and concentrations (0.1-10 μM) to achieve therapeutic effects. This resolves the contradiction by finding optimal parameter values that improve skin strength without requiring complex multi-component formulations.
Solution Approach 2:
The patent extracts and isolates specific active compounds (cannabinoids CBD and CBN) from complex plant extracts to create a simplified, targeted treatment. By taking out only the essential therapeutic components and eliminating unnecessary complexity, the treatment achieves improved skin strength while maintaining a relatively simple application regimen.
2Object-affected harmful factors
If topical cannabinoids are applied to modulate keratin expression, then blister formation is reduced, but the time required to achieve therapeutic effect increases
Solution Approach 1:
The patent applies preliminary action by continuously applying topical cannabinoids to gradually build up keratin expression and skin strength before blistering occurs. The treatment works preventively over time, with the cannabinoids accumulating and progressively modulating keratin gene expression, thereby reducing blister formation while establishing a sustained therapeutic effect.
Solution Approach 2:
The patent implements continuity of useful action through regular, repeated topical applications of cannabinoids. The continuous exposure ensures sustained modulation of keratin expression and maintenance of skin strength, preventing blister formation while the cumulative effect reduces the time needed to achieve therapeutic benefits.
3Productivity
If topical cannabinoids are applied to promote wound healing, then skin regeneration is improved, but the frequency of application required increases
Solution Approach 1:
The patent applies periodic action by establishing a scheduled regimen of topical cannabinoid applications (e.g., twice daily). This periodic treatment maintains sufficient drug levels in the skin to promote continuous wound healing and skin regeneration, balancing the need for frequent application with the desire to improve productivity without requiring constant treatment.
Data Source
AI summary
Mutations in keratin genes or the genes that regulate keratin expression can result in epithelial cells lacking sufficient structural integrity. The resulting disruption of connective tissue gives rise to inherited disorders such epidermolysis bullosa. It has been found that various cannabinoids (including mixtures of cannabidiols and cannabinol) upregulate expression of various keratins such that loss of function in other keratin genes may be compensated for. By way of this upregulation, these cannabinoids can be used to treat epidermolysis bullosa and other connective tissue disorders arising from intermediate filament dysfunction.